Clinical analysis of chronic hepatitis B with concurrent hepatitis e antigen and antibody during antiviral therapy
10.3969/j.issn.1006-5725.2015.11.016
- VernacularTitle:慢性乙型肝炎患者抗病毒治疗过程中出现HBeAg／抗－HBe双阳性的临床意义
- Author:
Xinxin WANG
;
Junjie WANG
;
Hao ZHANG
;
Nianhuan YANG
;
Guosheng YUAN
;
Jian ZHANG
;
Yuanping ZHOU
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Interferon;
Entecavir;
Concurrence of HBeAg and anti-HBe
- From:
The Journal of Practical Medicine
2015;(11):1778-1780
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical significance of chronic hepatitis B (CHB) with concurrent hepatitis e antigen (HBeAg) and antibody (anti-HBe) during antiviral therapy. Methods A total of 115 CHB patients with concurrent HBeAg and anti-Hbe detection during antiviral therapy were enrolled in this retrospective study. All patients received pegylated-IFN-alpha-2a (Peg-IFNα-2a, n = 50) or entecavir (ETV, n = 65) for antiviral treatment. Their biochemical virological and serological response and clinical outcome were detected and analyzed. Results Among the patients treated with Peg-IFNα-2a, 31 (62.0%) achieved HBeAg seroconversion and 6 (12.0%) achieved HBsAg seroconversion at the end of treatment. About 35.4% of patients, who received ETV, achieved HBeAg seroconversion and none of them achieved HBsAg seroconversion at the end of treatment (P < 0.05). Conclusion High rates of HBeAg seroconversion and HBsAg loss could be achieved in CHB patients, with co-existence of HBeAg and anti-HBe, who received Peg-IFNα-2a, but not ETV therapy.
